HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGT01 and HGT02, an tumor immunology for cancer. In addition, it offers HGT03, a protein degrader, and HGT04, a transcriptomics for cancer; and HGT05, a kinase inhibitor for liver cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation, and HGC245, a kinase inhibitor for glaucoma. The company’s nucleic acid drug pipeline includes HGP2142, an TGF-ß1 specific siRNA drug for liver cancer; HGN001, a nucleic acid drug for specific mutation of cancer target; and HGN002 for Solid tumor. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.